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INTRODUCTION
There is extensive evidence that the administration of certain live bacterial strains in large numbers with foods or supplements improves the microbial and nutritional balance of the intestinal tract of humans and animals, thus conferring a variety of beneficial effects (Malago, Koninkx and Marinsek Logar 2011) .
Increasing awareness of the benefits that probiotic bacteria provide in the gut and to general health has broadened the search for novel bacterial strains with probiotic activity. In vivo affordable experiments are desirable before accomplishing human clinical trials. These are needed to gather evidence to substantiate claims of prophylactic or therapeutic benefits, as required for final approval by regulatory authorities. In this context, a full preclinical analysis of the health-promoting properties of probiotic bacterial candidates should be conducted using integrated in vitro and in vivo approaches (FAO/WHO 2002; Sorokulova 2008; Donovan et al. 2012; Papadimitriou et al. 2015) . Non-mammalian vertebrates and invertebrate animal species are increasingly being proposed as cost-effective and ethically acceptable in vivo models (Dorer and Isberg 2006; Papadimitriou et al. 2015) . For instance, the wax moth larva Galleria mellonella has been used as a model to study infections caused by and host interactions with a number of pathogens, including several gastrointestinal bacterial pathogens (Ramarao, Nielsen-Leroux and Lereclus 2012; Tsai, Loh and Proft 2016) . Practical advantages of this in vivo model include the small size of the larvae, simplicity of handling, the feasibility of performing high number of replicates per test, ease of maintenance for testing conditions and reduced costs.
Galleria mellonella has also been used as a model to test the efficacy of antibiotic, antifungal or phage treatments (MesaArango et al. 2013; Abbasifar et al. 2014; Benthall et al. 2015) . Recently, attenuation of experimental candidiasis by a probiotic strain of Lactobacillus acidophilus, reduction of Listeria monocytogenes virulence by the cell-free supernatants of different probiotic strains and attenuation of L. monocytogenes and Staphylococcus aureus infections by different treatments with lactic acid bacteria were successfully demonstrated in G. mellonella larva models (Vilela et al. 2015; Grounta et al. 2016; Ribeiro et al. 2016; Upadhyay et al. 2016) .
In this study, we evaluated G. mellonella as an in vivo model to assess the protection conferred by probiotic microorganisms against gastrointestinal pathogens. The protective effect of two well-known and widely used probiotic strains, Lactobacillus rhamnosus GG and Clostridium butyricum Miyairi 588, was tested against three enteric pathogens causing infection in G. mellonella: Salmonella enterica Typhimurium, enteropathogenic Escherichia coli (EPEC) or L. monocytogenes (Joyce and Gahan 2010; Mukherjee et al. 2010; Leuko and Raivio 2012; Viegas et al. 2013) , and the results were contrasted with those obtained by a conventional in vitro agar spot test.
MATERIALS AND METHODS

Bacterial strains and culture preparations
Lactobacillus rhamnosus GG probiotic strain (ATCC 53103) was a kind gift from Lorenzo Morelli (Università Cattolica del Sacro Cuore, Piacenza, Italy). Clostridium butyricum Miyairi 588 probiotic strain was isolated from a commercially available singlestrain probiotic supplement. Its identification at the species level was confirmed by 16SrRNA sequencing, as described previously (Pourshaban et al. 2002) .
The gastrointestinal bacterial pathogens tested in this study were Salmonella enterica serovar Typhimurium (strain ATCC 14028), EPEC serotype O127:H6 (strain EF116, kindly provided by Stefano Morabito, EURL-VTEC, Istituto Superiore di Sanità, Roma, Italy) and L. monocytogenes serotype 4b (strain L90), which had been isolated during a large outbreak of febrile gastroenteritis in Italy (Franciosa et al. 2005) . All strains were maintained at -80
• C in microbank cryogenic vials (Prolab Diagnostics, Bromborough, UK For both in vivo and in vitro experiments, a single colony of each probiotic and gastrointestinal pathogen strains was selected from the agar plates, inoculated in 9 ml of MRS, TPGY or TS broth, and incubated overnight at 37
• C under aerobic or anaerobic conditions, depending on the bacterial species requirements.
Challenge and protection assays using Galleria mellonella larvae Bacteria inocula were prepared using cells cultured overnight, harvested by centrifugation (5000 × g for 15 min at 4
• C), washed twice with 0.9% sodium chloride solution, and resuspended in saline to give an optical density at 600 nm (OD 600 ) of ∼1. Experiments with G. mellonella larvae were performed as described by Ramarao, Nielsen-Leroux and Lereclus (2012) , with some modifications. Batches of last-stage larvae of G. mellonella weighing 200−300 mg were purchased (Mediterraneo Pesca e Subacquea, Rome, Italy) and used on the day of receipt. Injections were done with a 50 μl Hamilton microsyringe: larvae were considered dead when their color turned from pale yellow to dark brown and no movement was apparent on stimulation with light pressure.
The susceptibility of the G. mellonella larvae to the bacteria used in this study was tested with a challenge assay. Groups of 20 larvae each were inoculated by injection of 10 μl of serial dilutions of each probiotic or gastrointestinal pathogen bacterial suspension into the hemocoel through the last left proleg. The exact number of CFUs inoculated per larva was determined by plating dilutions of the inocula on the appropriate media. Following injection, larvae were placed in sterile petri plates, incubated in the dark at 37
• C and the number of dead larvae was counted and recorded daily for 3 days.
To assess the ability of the probiotic strains to protect against subsequent infection with the gastrointestinal pathogens (protection assays), separate groups of 20 larvae were injected as described above with either a probiotic strain at arbitrarily selected concentrations of ∼10 2 or ∼10 3 CFU/larva. After 2 h incubation in the dark at 37
• C, the pretreated larval groups were inoculated with 10 μl of each gastrointestinal pathogen at two different sublethal concentrations through the other (right) last proleg. The number of CFU in each inoculum was confirmed on suitable agar media. The larvae were then re-incubated in the dark at 37
Survival and mortality were monitored daily for 3 days. Control groups of 20 larvae each were included in all experiments. Two negative control groups consisted of nonmanipulated larvae and of larvae that were inoculated with 10 μl of sterile saline solution (trauma control group). In the protection assays, additional control groups were inoculated with a single pathogen or probiotic strain, at the same concentrations that were used for the probiotic−pathogen combination treatments. All experiments were carried out in triplicate, and only the experiments where all non-manipulated larvae survived until the third day were included in the analysis. 
Hemocyte density assay
Larvae were infected with the same method used for the G. mellonella protection assay. Hemocytes were collected from the hemocel of the larvae as described by Ribeiro et al. (2016) at 2 h post-injection. The hemocyte density was determined by using a Burker's counting chamber. Results were averaged from three replicates.
Antibacterial in vitro assay
The agar spot test described by Barbosa et al. (2005) was used, with some modifications, to assay the antibacterial activity of the probiotic strains against the gastrointestinal pathogens. Specifically, overnight broth cultures (10 μl) of L. rhamnosus GG and C. butyricum Miyairi 588 were spotted onto MRS or TPGY agar plates. After incubation for 48 h at 37
• C in anaerobiosis, the plates were overlaid with ∼10 9 cells of each test pathogen in 0.7% soft TS agar medium, and incubated for additional 24−48 h at 37
• C in aerobiosis. Then, the diameter of the inhibition zone around the spotted probiotics was measured. Similar experiments were performed by spotting the probiotic bacteria on TPGY or MRS agar plates without glucose. All experiments were carried out three times in triplicate.
Statistical analyses
All statistical analyses were performed using GraphPad Prism 6 software (GraphPad Software, La Jolla, USA). Data from triplicate experiments were pooled. Larval survival curves were plotted using the Kaplan−Meier method and differences in survival between groups were calculated using the log-rank test with P values ≤ 0.01 indicating statistical significance. Student's t test was used to compare the hemocyte densities. For the agar spot test, one-way analysis of variance (ANOVA) and Tukey's multiple comparisons tests were used to evaluate differences between means of inhibition areas for each strain. Levels of significance were set at P ≤ 0.05.
RESULTS
Susceptibility of the Galleria mellonella larvae to the bacterial strains (challenge assays)
The average mortality of G. mellonella larvae inoculated with saline to check the impact of physical trauma was 5% (Figs 1  and 2 ). We choose intrahemocelic rather than oral inoculation of the larvae because lack of mortality from Listeria monocytogenes infection following inoculation by the oral route has been reported (Fedhila et al. 2010) .
Mortality rates in infected larvae after 3 days of incubation approached 90% after inoculation of ∼1 × 10 4 CFU/larva of Salmonella enterica Typhimurium (strain ATCC 14028), 95% after inoculation of 1 × 10 5 CFU/larva of EPEC (strain EF116) and 80% after inoculation of 1 × 10 6 CFU/larva of L. monocytogenes (strain L90) (data not shown). For all three pathogens, larval killing was dependent on the number of cells injected in a dosedependent manner. The time-dose-mortality results and the Asterisk indicates a C. butyricum Miyairi 588 pretreated group with significantly enhanced survival compared with the pathogen-infected groups (≤0.01, log-rank test). The data are representative of three independent experiments (n = 20 for each group).
dose-dependent killing observed for the three pathogen strains were consistent with reported data on the susceptibility of G. mellonella larvae to other strains of the same pathogen species (Joyce and Gahan 2010; Mukherjee et al. 2010; Leuko and Raivio 2012; Viegas et al. 2013) . Given those results, the pathogen concentrations that we adopted as the challenge doses in the protection assays were ∼10 4 and 10 3 CFU/larva for S. enterica Typhimurium, ∼ 10 5 and 10 4 CFU/larva for EPEC and ∼10 6 and 10 5 CFU/larva for L. monocytogenes. In order to reduce the final bacterial loads in the G. mellonella larvae in the protection assays, concentrations of either 10 2 or 10 3 CFU/larva of L. rhamnosus GG or Clostridium butyricum Miyairi 588 probiotic strains were adopted for treatment prior to gastrointestinal microbial pathogen challenge (Figs 1 and 2 ).
Effects of pre-exposure to probiotics on experimental infection of Galleria mellonella larvae with gastrointestinal pathogens (protection assays)
Pretreatment with 10 3 CFU/larva of L. rhamnosus GG significantly increased the survival percentage of the G. mellonella larvae infected with S. enterica Typhimurium, EPEC or L. monocytogenes at the highest tested challenge doses, i.e. 10 4 , 10 5 or 10 6 CFU/larva, respectively. In fact, on day 3 after challenge, survival of larvae groups receiving 10 3 CFU/larva L. rhamnosus GG was 50% better than survival of control larvae given only the EPEC (P < 0.0001) or L. monocytogenes (P < 0.001) challenge, and 45% better than controls given only the S. enterica Typhimurium challenge (P < 0.001) (Fig. 1) . When larvae were pretreated with a lower dose of L. rhamnosus GG (10 2 CFU/larva), a similar 45% increase survival on day 3 was observed following challenge with 10 3 CFU/larva of S. enterica Typhimurium compared with controls (P < 0.001) (Fig. 1) . However, survival of G. mellonella larvae receiving 10 2 CFU/larva of L. rhamnosus GG and subsequently challenged with 10 4 CFU/larva EPEC or 10 5 CFU/larva L. monocytogenes was 30%, with no statistically significant differences between the groups pretreated with 10 2 CFU/larva of L. rhamnosus GG and the control groups (both p > 0.01, Fig. 1 ). Both tested doses (10 2 and 10 3 CFU/larva) of C. butyricum
Miyairi 588 protected the G. mellonella larvae from subsequent infections by S. enterica Typhimurium and L. monocytogenes at any tested challenge concentrations. On the final day of the experiments, the survival rates of probiotic pretreated larvae that were infected with S. enterica Typhimurium were 30%-35% better than controls (P < 0.01), and 40%-45% better than controls in pretreated larvae that were infected with L. monocytogenes (P < 0.001), depending on the test challenge concentrations (Fig. 2) . However, C. butyricum Miyairi 588 at both tested concentrations did not significantly protect larvae from subsequent infection with EPEC (Fig. 2) . In fact, pretreatment with either 10 3 or 10 2 CFU/larva of that probiotic strain increased survival by only 10% and 5%, respectively, of the G. mellonella larvae infected with 10 5 or 10 4 CFU/larva of EPEC (p > 0.01, Fig. 2 ).
Effects of probiotic pretreatments on Galleria mellonella hemocyte density
Control larvae inoculated with sterile saline solution had a mean hemocyte density of 0.46 × 10 6 / ml after 2 h incubation ( Table 1) .
The hemocyte densities in the larva groups inoculated with the probiotic strains L. rhamnosus GG or C. butyricum Miyairi 588 were significantly higher compared to the saline control group, 2 h after injection (Table 1) . Moreover, the hemocyte density significantly increased in the probiotic pretreated groups compared to the larva groups inoculated with the pathogens only (Table 1) . 
In vitro antibacterial activity
In vitro assessment of antibacterial activity using agar spot tests indicated that all three tested pathogens were inhibited by L. rhamnosus GG, although at different rates. The inhibition zones surrounding the L. rhamnosus GG spots were significantly larger with S. enterica Typhimurium and L. monocytogenes than those with EPEC (Fig. 3) . C. butyricum Miyairi 588 inhibited L. monocytogenes better than S. enterica Typhimurium, and did not inhibit growth of EPEC (Fig. 3) .
When the agar spot tests were performed in MRS or TPGY extract agar plates without glucose, no inhibition zones were observed around either probiotic strains with any of the tested pathogens (data not shown).
DISCUSSION
Protection against intestinal infections, including those of bacterial origin, is one of the best known health benefits provided by probiotics (Malago, Koninkx and Marinsek Logar 2011).
Competitive exclusion, production of antibacterial compounds such as organic acids and bacteriocins, enhancement of the epithelial gut barrier function, and/or modulation of the host innate and adaptive immune responses may be involved in the antagonism of probiotic bacteria against gastrointestinal bacterial pathogens (Bermudez-Brito et al. 2012) .
In vitro tests provide partial information on the antagonistic effects against bacterial pathogens, as they essentially determine the inhibition caused by the antibacterial agents produced by microorganisms when they are exposed to a pathogen in a liquid or solid medium or the adhesion properties of the tested microorganisms to gastrointestinal cell lines. Thus, results from in vivo testing can efficiently complement in vitro results (Bujalance et al. 2014; Papadimitriou et al. 2015) .
In this study, pre-administration of the probiotics Lactobacillus rhamnosus GG or Clostridium butyricum Miyairi 588 to Galleria mellonella larvae provided different degrees of protection against larval infections with the gastrointestinal pathogens Salmonella enterica Typhimurium, EPEC or L. monocytogenes. Thus, our results indicate that G. mellonella larva can be considered as an alternative in vivo model to evaluate the protection of candidate probiotic strains against gastrointestinal bacterial pathogens, confirming and extending previous findings by other authors who used different probiotic strains (or probiotic supernatants) and/or different target pathogens in similar G. mellonella larva models (Vilela et al. 2015; Grounta et al. 2016; Ribeiro et al. 2016; Upadhyay et al. 2016) .
The in vitro antibacterial activity of L. rhamnosus GG was consistent in part with the results obtained by the G. mellonella protection assay. Discrepancies included the observation that L. rhamnosus GG inhibited S. enterica Typhimurium and L. monocytogenes more strongly than EPEC, unlike its in vivo activity. Also, C. butyricum Miyairi 588 had weak to no in vitro inhibition of the three gastrointestinal pathogens, in contrast to the protection observed in vivo, at least against S. enterica Typhimurium and L. monocytogenes. The in vitro antibacterial activity against the gastrointestinal pathogens disappeared in agar media lacking glucose and other sugars, confirming indirectly that the production of acids from a rapid and easily fermentable carbon source (as glucose) by probiotic strains plays a primary role in the in vitro inhibition of pathogen growth (Bujalance et al. 2014) .
The in vivo protective effects conferred in the G. mellonella larvae by the probiotic strains could have been caused by different mechanisms, including enhancement of the larval immune system.
In fact, we found that the hemocyte density significantly increased in the probiotic pretreated larvae compared to the larvae inoculated with the pathogens only. Increase in the overall hemocyte density has been shown to reflect induction of the immune response in the G. mellonella larvae (Bergin, Brennan and Kavanagh 2003; Ribeiro et al. 2016) . Interestingly, in G. mellonella the immune response to infections shares features with the innate immune system of mammals (Tsai, Loh and Proft 2016; Wojda 2016) .
Therefore, the moderate differences between the in vivo and in vitro data likely result from different mechanisms of protective activity in vivo and antibacterial activity in vitro, supporting that in vivo and in vitro approaches provide complementary information.
In conclusion, the G. mellonella larvae represent a costeffective and simple in vivo model that could be used in conjunction with in vitro test(s) for preliminary screening the protective activity of probiotics against gastrointestinal pathogens. Our results point to the need of testing different concentrations of candidate probiotic strains against different species of gastrointestinal bacterial pathogens in order to standardize and implement the G. mellonella protection assay for future use.
Further studies with a larger number of probiotics and gastrointestinal pathogens and better characterization of the in vivo protective effects are needed to validate the G. mellonella model.
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